Cellectis Licenses TAL-effector Patents from University of Minnesota

Jan 21, 2011

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cellectis today announced a licensing agreement with the University of Minnesota giving it exclusive rights to use inventions related to TAL effector-mediated DNA recognition and cleavage.

Financial and other terms of the deal were not disclosed.

The technology was co-developed at the University of Minnesota and Iowa State University, and in a statement, Cellectis said that it shows promising results in genome engineering. It is complementary to Cellectis' proprietary meganuclease technology, the Paris-based genome engineering firm added.

Filed under

ABRF

University of Minnesota

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.